11.20.2018
Diagnostics
$1,716,684.00
53 months
Identification and Validation of a Predictive Serological Biomarker Signature for Therapeutic Response to Anti-TNF, Vedolizumab, and Ustekinumab
Funding to identify protein-based biomarkers that will allow for better personalized treatment of Crohn's disease patients.